# Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome

> **NCT00017862** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (—)

## Conditions studied

- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** SCH55700

## Key facts

- **NCT ID:** NCT00017862
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** —
- **Final completion:** 2003-06
- **Target enrollment:** 10 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017862, "Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00017862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*